Drugs / Murepavadin
Murepavadin
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02897869 | Apr → Aug 2016 | — | Polyphor Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02165332 | Jul → Nov 2014 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02156323 | Jul 2014 → Mar 2015 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02165293 | Jun → Sep 2014 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02110459 | Apr 2013 → Jul 2015 | impaired renal function disease | Polyphor Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02096315 | Dec 2013 → Nov 2015 | bronchiectasis, respiratory tract infectious disorder | Polyphor Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT02096328 | Oct 2013 → Dec 2015 | respiratory tract infectious disorder | Polyphor Ltd. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03582007 | Oct 2018 → Jul 2019 | pneumonia | Polyphor Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT03409679 | Mar 2018 → Jul 2019 | pneumonia | Polyphor Ltd. | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Murepavadin | “Pharmacokinetics, Tolerability, and Safety of Murepavadin, a Novel Antipseudomonal Antibiotic, in Subjects with Mild, Moderate, or Severe Renal Function Impairment.” PMID 30012756 ↗ Aug 2018 |
| Known as | Murepavadina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3946483 ↗ |
| Known as | Murepavadine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3946483 ↗ |
| Known as | POL7080 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02897869 ↗ |
| Known as | RO7033877 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02165293 ↗ |
| Modality | Peptide | “a novel peptide antibiotic” PMID 30012756 ↗ Aug 2018 |
| Route | Intravenous | “Intravenous infusion” NCT02096315 ↗ |